

招商银行全资附属机构 A Wholly Owned Subsidiary Of China Merchants Bank

FriendTimes Inc. (6820 HK)

Attractive valuation with new games to come

FriendTimes delivered in-line FY20 results, with topline/bottom line +29% /21% YoY. Paying out ratio at 43.7% surprised us. With existing games trend priced in, we suggest to look beyond FY20 earnings, and move into new titles in FY21E. There are three key titles in 2021 pipeline, including female Xianxia games. (e.g. TLJ <此生无白> to be launched on 28 Apr) and modern woman game (2H21E). We trimmed its earnings by 7%/3% in FY21/22E to reflect new games S&M efforts, but maintain our TP of HK\$4.0 (12x FY21E P/E) by rolling over to FY21E multiple. Maintain BUY with attractive valuation and multiple catalysts to come.

- Solid FY20 with dividend surprise. FY20 revenue grew 29.2% YoY, in line with our estimates despite 4% below consensus. Adj. net profit came in at RMB503.5mn, up 21% YoY, in line with buyside expectation and consensus. We are impressed by its dividend at HK\$0.12 per share, with paying out ratio at 43.7% (vs. our expectation of 30%).
- FoE grossing steps into stable stage. After grossing peak in Jul 2020, FoE <浮生> kept stable at Top 20-30 in grossing rank in early 2021. We estimate its monthly grossing at around RMB100mn in Jan & Feb, in which mainland China/South Korea/HK, M&T version at RMB70mn/RMB16mn/RMB10mn. FoE would launch its Japanese version and English version in Apr/May. We forecast FoE & other existing games to contribute RMB1bn & RMB700mn annual grossing in FY21E, in which FoE with higher margin. The existing games grossing trend has been well anticipated by the market, more upside would come from 2021E new games, in our view.
- Three new titles in 2021E to bring further upside. We suggest market to eye on new titles in 2021E, including female Xianxia games. (e.g. Ftae: The Loved Journey <此生无白>, Promise of Lingyun <凌云诺>) and modern woman game (A Story of Lala's: Rising Star <杜拉拉升职记>). <TLJ > would launch on 28 Apr, and mgmt reiterated confidence on its performance based on testing data. We estimate its monthly peak grossing at RMB80mn, if executed well. We expect PoL and Lala to be launched in 2H21E, in which Lala is highly-anticipated by the market.
- Maintain BUY. The stock is trading at 8.5x FY21E P/E, largely below industry average of 15x. We trimmed its earnings by 7%/3% in FY21/22E, but maintain our TP of HK\$4.0 (12x FY21E P/E) by rolling over to FY21E multiple. We suggest to accumulate on dips, as more catalysts to come (e.g. <此生无白> launch, ToE Japanese & English version, and solid 1H21E result).

Earnings Summary

Larinings Summary					
(YE 31 Dec)	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	1,689	2,182	2,844	3,416	3,994
YoY change (%)	15%	29%	30%	20%	17%
Adj. net income (RMB mn)	416	504	607	766	928
Adj. EPS (RMB)	0.19	0.23	0.28	0.35	0.42
YoY growth (%)	23%	21%	21%	26%	21%
Consensus EPS (RMB)	NA	NA	0.30	0.36	NA
P/E (x)	12.5	10.3	8.5	6.8	5.6
P/S (x)	3.6	2.8	2.2	1.8	1.5
Yield (%)	0.0	4.7%	3.9%	4.1%	3.9%
ROE (%)	32%	32%	28%	26%	24%
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIS estimates

BUY (Maintain)

Target Price HK\$4.0 (Previous TP HK\$4.0)
Up/Downside +42.8%
Current Price HK\$2.8

China Internet Sector

Sophie Huang

(852) 3900 0889 sophiehuang@cmbi.com.hk

Miriam Lu

852 3761 8728 miriamlu@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	6,281
Avg 3 mths t/o (HK\$ mn)	10.44
52w High/Low (HK\$)	4.08/ 1.62
Total Issued Shares (mn)	2,181
Caurage Diagrahara	

Source: Bloomberg

Shareholding Structure
Eternal Heart Holding

Eternal Heart Holding	43.0%
Warm Sunshine	8.7%
Ling Long Holding	8.6%
Source: Bloomberg	

Share Performance

	Absolute	Relative
1-mth	13.1%	19.5%
3-mth	50.0%	36.1%
6-mth	15.3%	-4.8%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: KPMG

Related Reports

- Looking beyond 1H20 earnings 2
 Sep 2020
- Investments to enrich category 7
 Jul 2020
- 3. More catalysts to come 9 Jun 2020



Figure 1: Earnings revision

		New			Old		Diff (%)			
RMB mn, Dec-YE	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	
Revenue	2,844	3,416	3,994	2,673	3,145	NA	6.4%	8.6%	NA	
Gross Profit	1,851	2,231	2,608	1,740	2,054	NA	6.4%	8.6%	NA	
Operating Profit	654	828	1,004	708	854	NA	-7.6%	-3.0%	NA	
Adj. net profit	607	766	928	654	787	NA	-7.2%	-2.6%	NA	
Adj. EPS (RMB)	0.28	0.35	0.42	0.30	0.36	NA	-7.2%	-2.6%	NA	
Gross Margin	65.1%	65.3%	65.3%	65.1%	65.3%	NA	0.0ppts	0.0ppts	NA	
Operating Margin	23.0%	24.2%	25.1%	26.5%	27.1%	NA	-3.5ppts	-2.9ppts	NA	
Adj. net margin	21.3%	22.4%	23.2%	24.5%	25.0%	NA	-3.1ppts	-2.6ppts	NA	

Source: CMBIS estimates

Figure 2: CMBIS estimates vs consensus

	CMBIS			Consensus			Diff (%)			
RMB mn, Dec-YE	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	
Revenue	2,844	3,416	3,994	2,916	3,322	NA	-2.5%	2.8%	NA	
Gross Profit	1,851	2,231	2,608	1,901	2,161	NA	-2.6%	3.2%	NA	
Operating Profit	654	828	1,004	691	823	NA	-5.4%	0.7%	NA	
Adj. net profit	607	766	928	655	779	NA	-7.3%	-1.6%	NA	
Adj. EPS (RMB)	0.28	0.35	0.42	0.30	0.36	NA	-9.2%	-3.6%	NA	
Gross Margin	65.1%	65.3%	65.3%	65.2%	65.1%	NA	-0.1ppts	+0.2ppts	NA	
Operating Margin	23.0%	24.2%	25.1%	23.7%	24.8%	NA	-0.7ppts	-0.5ppts	NA	
Adj. net margin	21.3%	22.4%	23.2%	22.5%	23.4%	NA	-1.1ppts	-1.0ppts	NA	

Source: CMBIS estimates, Bloomberg

Figure 3: FriendTimes' FY20 review

RMB ('000), Dec-YE	2019	2020	YoY
Revenue	1,689,051	2,182,257	29%
Cost of sales	(586,974)	(713,912)	22%
Gross profit	1,102,077	1,468,345	33%
Sales and marketing expenses	(393,284)	(612,386)	56%
Research and development expenses	(223,602)	(264,692)	18%
General and administrative expenses	(62, 128)	(46,326)	-25%
Other income	23,686	(1,918)	-108%
Operating (loss)/profit	446,749	543,023	22%
Finance costs	(289)	(110)	-62%
Share of loss of an associate	(9)	(1,638)	18100%
Changes in fair value of equity investment measured at fair value			
through profit or loss	(8,247)	(14,668)	
Profit before taxation	438,204	526,607	20%
Income tax expense	(22,677)	(23,088)	2%
Profit for the year	415,527	503,519	21%
Margin Analysis			
Gross margin	65%	67%	
Operating margin	26%	25%	
Net margin	25%	23%	
Growth Analysis			
Revenue		29%	
Gross profit		33%	
Operating profit		22%	
Net profit		21%	

Source: Company data



Financial Summary

YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E	YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue	1,689	2,182	2,844	3,416	3.994	Pre-tax Income	438	527	651	822	996
Games	1,689	2,182	2,844	3,416	3,994	D&A	13	11	12	52	53
Others	-,	_,	_,	-,	-	Change in WC	(51)	(21)	(90)	(21)	(21)
						Others	(59)	59	(55)	(76)	(89)
cogs	(587)	(714)	(993)	(1,185)	(1,386)	Operating CF	342	575	519	778	939
Gross profit	1,102	1,468	1,851	2,231	2,608	3				_	
p. 2.1.	.,	.,	.,	_,	_,	Capex	(139)	(77)	(60)	(60)	(60)
S&M	(393)	(612)	(828)	(1,008)	(1,158)	Others	(96)	(51)	14	26	30
R&D	(224)	(265)	(350)	(376)	(419)	Investing CF	(236)	(128)	(46)	(34)	(30)
G&A	(62)	(46)	(57)	(68)	(80)		(===)	(/	(/	(- ')	()
Other income	24	(2)	37	49	54	Equity raised	500	_	_	_	
Operating profit	447	543	654	828	1,004	Change of debts	-	_	48	48	48
operating profit	771	343	004	020	1,004	Others	(181)	(222)	(3)	(6)	(9)
Finance costs	(0)	(0)	(3)	(6)	(9)	Financing CF	319	(222)	45	42	39
	(8)	` ,	(3)	(0)	0	rmancing Cr	319	(222)	40	42	33
Other gains, net Pre-tax Income	438	(16) 527	651	822	996	Not change in each	425	225	518	786	948
Pre-tax income	430	527	1 60	022	996	Net change in cash					
	(00)	(00)	(4.4)	(50)	(00)	Cash (beg of yr)	473	893	1,093	1,611	2,396
Income Tax	(23)	(23)	(44)	(56)	(68)	FX	(4)	(25)	-	-	0.045
MI	-		-		-	Cash (end of yr)	893	1,093	1,611	2,396	3,345
Net profit	416	504	607	766	928						
Adj. net profit	416	504	607	766	928						
Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E	YE 31 Dec	FY19A	FY20A	FY21F	FY22E	FY23F
12 01 200 (12)	246	388	447	455	462			20/1			
Non-current assets						Sales mix (%)					
Fixed asset	202	264	326	336	344	Games	100.0	100	100.0	100.0	100.0
Right-of-use assets	9	8	6	5	4	Others	0.0	0.0	0.0	0.0	0.0
Intangible assets	8	4	1	1	1	Total	100.0	100.0	100.0	100.0	100.0
Others	28	113	113	113	113						
3.1.0.0		110			110	Growth rate (%)					
Current assets	1,265	1,404	2,016	2,859	3,865	Revenue	15.3	29.2	30.3	20.1	16.9
Cash	893	1,093	1,611	2,396	3,345	Gross profit	20.0	33.2	26.1	20.5	16.9
Trade receivables	219	181	256	307	359	EBIT	23.0	21.5	20.5	26.5	21.3
Other current assets	153	130	150	155	161	Net profit	23.4	21.2	20.6	26.2	21.1
Other current assets	100	130	130	133	101	Net profit	25.4	21.2	20.0	20.2	21.1
Current liabilities	196	221	254	333	413	P&L ratios (%)					
Bank loans	-	-	48	96	144	Gross Margin	65.2	67.3	65.1	65.3	65.3
Trade and other payables	135	143	40	47	55	Pre-tax margin	25.9	24.1	22.9	24.1	24.9
Lease liabilities	3	1	1	1	1	Adj. net margin	24.6	23.1	21.3	22.4	23.2
Other current liabilities	58	77	165	188	212	Effective tax rate	5.2	4.4	6.8	6.8	6.8
	0	5	26	31	36	Returns (%)					
Non-current liabilities	9				26	ROE	31.8	32.1	27.8	26.0	23.9
	9	5	26	31	36						
Contract liabilities		5	26	31 -	-			28.1	24.6	23.1	21.4
Contract liabilities Lease liabilities		5 - -	26 - -	31 - -	- -	ROA	27.5				21.4
Contract liabilities Lease liabilities		5 - -	26 - -	31 - -	- -	ROA	27.5	28.1	24.6	23.1	21.4
Non-current liabilities Contract liabilities Lease liabilities Others Total Equity		5 - - 1,566	26 - - 2,184	2,950	3,878						

Source: Company data, CMBIS estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings

BUY
Stock with potential return of over 15% over next 12 months
SELL
Stock with potential return of +15% to -10% over next 12 months
SELL
Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.